Residency · Residency · Family Medicine

Heart Failure in the Outpatient Setting

Overview

Heart failure affects over 6 million Americans, and its prevalence continues to rise as the population ages and survival from myocardial infarction improves. Family physicians play a central role in early detection, initiation and optimization of guideline-directed medical therapy (GDMT), volume management, and coordinated co-management with cardiology. The outpatient management of heart failure has been transformed in recent years by the recognition that multiple drug classes should be started simultaneously rather than sequentially, and that some agents benefit patients regardless of diabetes status.

Classification

By Ejection Fraction

Heart failure is classified by left ventricular ejection fraction into four categories. HFrEF (heart failure with reduced ejection fraction) is defined as an LVEF of 40% or below and has the strongest evidence base for pharmacotherapy. HFmrEF (mildly reduced EF), with LVEF 41 to 49%, has emerging evidence supporting treatment similar to HFrEF. HFpEF (preserved EF), with LVEF of 50% or above, historically had limited pharmacotherapy options, but SGLT2 inhibitors have now established an evidence base for this phenotype. HFimpEF (improved EF) describes patients whose EF was previously reduced but has risen above 40% on therapy; GDMT should be continued, as discontinuation frequently triggers relapse.

NYHA Functional Classification

The NYHA classification captures functional limitation. Class I patients have no limitation of physical activity. Class II involves slight limitation, with symptoms during ordinary activity but comfort at rest. Class III represents marked limitation, with symptoms from less than ordinary activity. Class IV patients experience symptoms at rest and cannot perform any physical activity without discomfort.

ACC/AHA Stages

The ACC/AHA staging system captures disease progression. Stage A identifies patients at risk (with hypertension, diabetes, obesity, or coronary artery disease) but without structural heart disease or symptoms. Stage B indicates structural heart disease (such as left ventricular hypertrophy, reduced EF, or valvular disease) without symptoms. Stage C describes structural heart disease with current or prior symptoms. Stage D represents refractory heart failure requiring advanced therapies such as a left ventricular assist device, cardiac transplantation, or palliative care.

Diagnosis

Clinical Presentation

Dyspnea on exertion is the most sensitive symptom of heart failure. Other presenting features include orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema, weight gain, fatigue, and exercise intolerance. On examination, jugular venous distension and hepatojugular reflux indicate elevated right-sided filling pressures. An S3 gallop is the most specific physical examination finding. Pulmonary crackles are a late finding and are often absent in chronic, compensated heart failure.

Diagnostic Workup

BNP or NT-proBNP testing supports the diagnosis, with BNP above 100 pg/mL or NT-proBNP above 300 pg/mL being suggestive. However, obesity can falsely lower BNP values, and renal dysfunction can elevate NT-proBNP independent of heart failure. Echocardiography is essential for assessing ejection fraction, evaluating valvular function, assessing diastolic function, and measuring chamber sizes. An ECG should be obtained to evaluate rhythm, left ventricular hypertrophy, prior MI patterns, and bundle branch block (LBBB is relevant for cardiac resynchronization therapy candidacy). Laboratory studies should include a CBC, comprehensive metabolic panel, TSH, iron studies (iron deficiency is common in heart failure), lipid panel, and HbA1c. Chest X-ray may reveal cardiomegaly, pulmonary congestion, or pleural effusions.

Etiology Workup

Ischemic heart disease is the most common cause of heart failure, and stress testing or coronary angiography should be considered. Non-ischemic causes include viral myocarditis, alcohol-related cardiomyopathy, peripartum cardiomyopathy, familial dilated cardiomyopathy, valvular disease, hypertensive heart disease, and tachycardia-mediated cardiomyopathy. Cardiac MRI can help clarify etiology when the cause remains uncertain.

Guideline-Directed Medical Therapy for HFrEF

The Four Pillars of GDMT

Current guidelines recommend initiating all four foundational drug classes simultaneously or in rapid sequence, rather than following the older approach of starting one class at a time and titrating to target before adding the next. Even low doses of all four agents together provide greater benefit than full-dose therapy with only one.

The first pillar is neurohormonal blockade with an ACE inhibitor, ARB, or preferably an angiotensin receptor-neprilysin inhibitor (ARNI). Sacubitril-valsartan is preferred over ACE inhibitors or ARBs based on the PARADIGM-HF trial, which demonstrated a 20% mortality reduction. Dosing starts at 24/26 mg twice daily and targets 97/103 mg twice daily. A mandatory 36-hour washout from ACE inhibitors is required before starting ARNI to avoid angioedema. Potassium and creatinine should be monitored, with up to a 30% rise in creatinine generally tolerated.

The second pillar is beta-blockade. Only three beta-blockers have mortality evidence in HFrEF: carvedilol, metoprolol succinate (not tartrate), and bisoprolol. These should be started at low doses when the patient is euvolemic and titrated every two weeks. Carvedilol starts at 3.125 mg twice daily targeting 25 mg twice daily (50 mg twice daily for patients over 85 kg). Metoprolol succinate starts at 12.5 to 25 mg daily targeting 200 mg daily. Beta-blockers should not be initiated during acute decompensation but should not be discontinued during hospitalization for mild decompensation.

The third pillar is mineralocorticoid receptor antagonism with spironolactone 25 to 50 mg daily or eplerenone 25 to 50 mg daily. The RALES trial demonstrated a 30% mortality reduction with spironolactone. These agents are contraindicated when eGFR is below 30 or potassium exceeds 5.0 mEq/L. Potassium and creatinine should be monitored within one week of initiation, at one month, and then every three months.

The fourth pillar is SGLT2 inhibition with dapagliflozin or empagliflozin. The DAPA-HF and EMPEROR-Reduced trials demonstrated approximately 25% reductions in heart failure hospitalization and cardiovascular death. The benefit is independent of diabetes status, meaning these agents should be prescribed to all patients with HFrEF regardless of whether they have diabetes. Dapagliflozin can be started at eGFR levels as low as 20, and the risk of hypoglycemia in non-diabetic patients is low.

Additional Therapies

Hydralazine combined with isosorbide dinitrate is specifically indicated for Black patients with NYHA class III to IV symptoms already on standard GDMT, based on the A-HeFT trial, and can also be used when ARNI, ACE inhibitors, and ARBs are not tolerated. Ivabradine is an option for patients in sinus rhythm with a heart rate of 70 bpm or above despite maximally tolerated beta-blocker therapy. Loop diuretics (furosemide, bumetanide, torsemide) are essential for volume management but do not provide a mortality benefit. Digoxin reduces heart failure hospitalizations but has no mortality benefit and a narrow therapeutic window. IV iron replacement with ferric carboxymaltose should be given when ferritin is below 100 or when ferritin is 100 to 300 with transferrin saturation below 20%, as supported by the AFFIRM-AHF trial.

Device Therapy

An implantable cardioverter-defibrillator (ICD) is indicated for primary prevention in patients with LVEF of 35% or below despite at least three months of optimal GDMT, NYHA class II or III, and a life expectancy exceeding one year. Cardiac resynchronization therapy (CRT) is indicated for patients with LVEF of 35% or below, left bundle branch block with QRS duration of 150 ms or greater, and NYHA class II to IV symptoms on GDMT.

HFpEF Management

The treatment landscape for HFpEF has been transformed by SGLT2 inhibitor trials. The EMPEROR-Preserved and DELIVER trials demonstrated benefit across the ejection fraction spectrum, establishing SGLT2 inhibitors as the first medication class with robust evidence in HFpEF. Diuretics remain the cornerstone for volume management. Aggressive treatment of comorbidities, including hypertension, atrial fibrillation, coronary artery disease, obesity, and obstructive sleep apnea, is critical. Exercise training improves functional capacity. Spironolactone may benefit select HFpEF patients based on the TOPCAT trial, though results showed regional variation. GLP-1 receptor agonists represent a promising new direction for obese HFpEF patients, with the STEP-HFpEF trial showing that semaglutide improved symptoms and six-minute walk distance.

Monitoring and Follow-Up

Post-discharge follow-up should occur within seven days. GDMT should be titrated every one to two weeks as tolerated. Patients should weigh themselves daily and report gains of 2 pounds in a day or 5 pounds in a week, which may signal fluid retention. Serial BNP or NT-proBNP levels are useful for tracking trends over time but should not be interpreted in isolation. Annual influenza and pneumococcal vaccinations are recommended. Sodium restriction to less than 2 grams per day is strongly recommended despite limited direct trial evidence. Fluid restriction to 1.5 to 2 liters per day is reserved for patients with refractory congestion. Cardiac rehabilitation should be offered, supported by the HF-ACTION trial.

When to Refer to Cardiology/Advanced HF

Referral to cardiology or an advanced heart failure specialist is appropriate at the time of new diagnosis for etiology workup and GDMT optimization, when LVEF is 35% or below for device evaluation, when symptoms persist despite optimized GDMT, after two or more hospitalizations in 12 months, when advanced therapies such as LVAD or transplant merit consideration, or when Stage D symptoms develop.

<image>A four-quadrant infographic illustrating the four pillars of HFrEF GDMT. Each quadrant shows one drug class (ARNI, beta-blocker, MRA, SGLT2i) with starting dose, target dose, key monitoring parameters, and the landmark trial name with its primary outcome reduction percentage. Include a central circle indicating that all four should be initiated simultaneously rather than sequentially.</image>

<image>A clinical pathway diagram for heart failure diagnosis starting from presenting symptoms (dyspnea, edema, fatigue), through initial workup (BNP, echo, ECG, labs), branching into HFrEF vs HFpEF classification, and showing the different treatment algorithms for each phenotype. Include boxes for device therapy eligibility criteria on the HFrEF pathway.</image>

<image>A patient-facing visual education tool for heart failure self-management showing a daily monitoring checklist: daily weight log with alert thresholds, dietary sodium tracking, medication adherence chart, symptom diary, and when-to-call-the-doctor red flags. Use simple icons and large text suitable for patient handouts.</image>

Clinical Pearls

Starting all four pillars of GDMT simultaneously, even at low doses, is superior to the outdated sequential approach of maximizing one drug before adding the next. Metoprolol tartrate and metoprolol succinate are not interchangeable in heart failure; only the succinate (extended-release) formulation has mortality evidence in HFrEF. ARNI and ACE inhibitors must never be used concurrently, and a mandatory 36-hour washout period must be observed when transitioning. Iron deficiency is present in up to 50% of heart failure patients and should be treated with intravenous iron even in the absence of anemia, as it independently contributes to symptoms and exercise intolerance. SGLT2 inhibitors benefit heart failure patients regardless of diabetes status, representing a true paradigm shift in management. Beta-blockers should not be stopped during mild decompensation; dose reduction is preferable to abrupt discontinuation, which can precipitate hemodynamic deterioration. BNP levels may be disproportionately low in obese patients, so clinical judgment must complement biomarker interpretation. Palliative care should be introduced early in Stage D heart failure as a complement to, not a replacement for, active disease management.

References

• Heidenreich PA et al. 2022 AHA/ACC/HFSA Guideline for Management of Heart Failure. Circulation. 2022
• McMurray JJV et al. PARADIGM-HF: Angiotensin-Neprilysin Inhibition vs. Enalapril in HF. NEJM. 2014
• McMurray JJV et al. DAPA-HF: Dapagliflozin in HFrEF. NEJM. 2019
• Anker SD et al. EMPEROR-Preserved: Empagliflozin in HFpEF. NEJM. 2021
• Solomon SD et al. DELIVER: Dapagliflozin in HFmrEF and HFpEF. NEJM. 2022
• Kosiborod MN et al. STEP-HFpEF: Semaglutide in Obese HFpEF. NEJM. 2023
• Pitt B et al. RALES: Spironolactone in Severe HF. NEJM. 1999
• Taylor AL et al. A-HeFT: Isosorbide Dinitrate-Hydralazine in Black Patients with HF. NEJM. 2004

Read this lecture as Markdown